H.C. Wainwright & Co. reaffirmed its Buy rating and $15.00 price target for Emergent BioSolutions stock (NYSE:EBS). The ...
Shionogi & Co. has been awarded a $375 million project agreement by the Biomedical Advanced Research and Development ...
Moderna, Inc. (NASDAQ:MRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The ...
While Moderna Inc. plans to cut its expenses by $1 billion in 2025, the company has received a little breathing room by a hefty U.S. Department of Health and Human Services (HHS) grant. The Biomedical ...
Micron Biomedical, a life science company developing the world’s first needle-free technology for drugs and vaccines that is based on dissolvable microarrays, ...
proudly announces its selection as a Concept Stage winner in the prestigious United States Biomedical Advanced Research and Development Authority (BARDA) Patch Forward Prize. Achieved in ...
Emergent BioSolutions (EBS) announced that the Biomedical Advanced Research and Development Authority executed a contract modification for the second option period, valued at approximately $16.7 ...
has been named a Concept Stage winner of the United States Biomedical Advanced Research and Development Authority’s (BARDA’s) $50 million Patch Forward Prize. This press release features ...
today announced the company won the Biomedical Advanced Research and Development Authority (BARDA) Patch Forward competition and presented at an event during the J.P. Morgan Healthcare Conference ...